Targeted Therapy
253 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (74)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Revumenib |
EZH2 / Menin Inhibitor | Hematologic | ||
|
Molecule
Revumenib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
||||
Romidepsin |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Romidepsin
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Selinexor |
XPO1 (Exportin-1) Inhibitor | Hematologic (Multiple Myeloma/DLBCL) | ||
|
Molecule
Selinexor
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma/DLBCL)
Drug Class / Mechanism
XPO1 (Exportin-1) Inhibitor |
||||
Sonrotoclax |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
Sonrotoclax
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
Sorafenib (AML use) |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Sorafenib (AML use)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Spebrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Spebrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Tazemetostat |
EZH2 / Menin Inhibitor | Hematologic | ||
|
Molecule
Tazemetostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
||||
Tirabrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Tirabrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Tucidinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Tucidinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Valemetostat |
EZH2 / Menin Inhibitor | Hematologic | ||
|
Molecule
Valemetostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
||||
Vecabrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Vecabrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Vodobatinib |
BCR-ABL Tyrosine Kinase Inhibitor | Hematologic (Leukemia) | ||
|
Molecule
Vodobatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
||||
RevumenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
|
RomidepsinTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
SelinexorTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma/DLBCL)
Drug Class / Mechanism
XPO1 (Exportin-1) Inhibitor |
|
SonrotoclaxTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
Sorafenib (AML use)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
SpebrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
TazemetostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
|
TirabrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
TucidinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
ValemetostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
|
VecabrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
VodobatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
|